West Pharmaceutical Services, Inc. WST
370.44
(3.16)
(0.85%)
as of 25 Sep
- Market cap
- $26.3B
- P/E
- 47.1×
Follow WST
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
West Pharmaceutical Services, Inc. (WST) P/E ratio
As of 25 September 2026, West Pharmaceutical Services, Inc. (WST) trades at a P/E ratio of 47.1×. Over the past ten years it has ranged from 24.7× (November 2022) to 74.4× (September 2020); the current reading is higher than 61% of that period. That is above the Medical Instruments & Supplies industry median of 34.2× and above the Healthcare sector median of 22.7×.
P/E ratio, daily
Annual
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 40.3× | (16.99%) |
| FY2024 | 48.5× | 11.06% |
| FY2023 | 43.7× | 46.70% |
| FY2022 | 29.8× | (43.35%) |
| FY2021 | 52.6× | (12.96%) |
| FY2020 | 60.4× | 31.40% |
| FY2019 | 46.0× | 31.31% |
| FY2018 | 35.0× | (27.87%) |
| FY2017 | 48.5× | 13.16% |
| FY2016 | 42.9× | (5.27%) |
Quarterly
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 45.6× | 36.86% |
| Mar 2026 | 33.3× | (17.26%) |
| Dec 2025 | 40.3× | 4.27% |
| Sep 2025 | 38.6× | 18.66% |
| 42 more quarters | Free account |
Against its own ten years
Low 24.7×
High 74.4×
Ten-year median
44.3×
Current reading's percentile
61
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| BAX Baxter International Inc. compare | n/m |
| SOLV Solventum Corporation compare | 10.9× |
| COO The Cooper Companies, Inc. compare | 18.9× |
| RMD ResMed Inc. compare | 21.3× |
| WST West Pharmaceutical Services, Inc. | 47.1× |
| ALC Alcon compare | 49.2× |
| BDX Becton, Dickinson and Company compare | 55.4× |
| RGEN Repligen Corporation compare | 253× |
| MDLN Medline Inc. compare | — |
| Medical Instruments & Supplies industry median | 34.2× |
| Healthcare sector median | 22.7× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)
More on WST
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement